138 related articles for article (PubMed ID: 37805393)
1. [Plurihormonal PIT1-lineage pituitary neuroendocrine tumors: a clinicopathological study].
Duan ZJ; Feng J; Zhao HQ; Wang HD; Gui QP; Zhang XF; Ma Z; Hu ZJ; Xiang L; Qi XL
Zhonghua Bing Li Xue Za Zhi; 2023 Oct; 52(10):1017-1024. PubMed ID: 37805393
[No Abstract] [Full Text] [Related]
2. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
3. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
4. Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience.
Mihajlović M; Pekić S; Doknić M; Stojanović M; Rašić D; Miljić D; Petakov M; Manojlović Gačić E
Int J Surg Pathol; 2024 May; 32(3):470-477. PubMed ID: 37438981
[No Abstract] [Full Text] [Related]
5. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
Xie J; Wu ZB
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
[TBL] [Abstract][Full Text] [Related]
6. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
[TBL] [Abstract][Full Text] [Related]
7. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
[TBL] [Abstract][Full Text] [Related]
8. The clinical presentation of PIT1 positive pituitary neuroendocrine tumor immunonegative for growth hormone, prolactin, and thyroid stimulating hormone with analysis of clinical and immunostaining dissociation.
Hong S; Shinya Y; Trejo-Lopez JA; Gruber LM; Erickson D; Bendok BR; Chaichana KL; Atkinson JL; Marino MJ; Donaldson AM; Stokken JK; Westphal SA; Chang AY; Samson SL; Choby GW; Van Gompel JJ
Clin Neurol Neurosurg; 2024 Jan; 236():108075. PubMed ID: 38056042
[TBL] [Abstract][Full Text] [Related]
9. Follicular cells in pituitary neuroendocrine tumors.
Delfin L; Mete O; Asa SL
Hum Pathol; 2021 Aug; 114():1-8. PubMed ID: 33991528
[TBL] [Abstract][Full Text] [Related]
10. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
Luo M; Tang R; Wang H
J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
[TBL] [Abstract][Full Text] [Related]
11. A Case of an Immature PIT1-Lineage Pituitary Neuroendocrine Tumor of the Nasopharynx.
Peters J; Gryn O; Gerka-Stuyt J
Cureus; 2023 Sep; 15(9):e44985. PubMed ID: 37701167
[TBL] [Abstract][Full Text] [Related]
12. Plurihormonal pituitary macroadenoma: a case report.
Allehaibi E; AlMalki MH; Brema I
J Med Case Rep; 2021 Jul; 15(1):407. PubMed ID: 34321093
[TBL] [Abstract][Full Text] [Related]
13. An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism.
Asa SL; Ezzat S
J Clin Med; 2021 May; 10(11):. PubMed ID: 34067494
[TBL] [Abstract][Full Text] [Related]
14. Digital image analysis allows objective stratification of patients with silent PIT1-lineage pituitary neuroendocrine tumors.
Zhao J; Ji C; Cheng H; Ye Z; Yao B; Shen M; Shou X; Zhou X; Ye H; Zhang Z; Chen H; Wang Y; He F; Zhao Y; Gong W; Zhang Q; Qiao N
J Pathol Clin Res; 2023 Nov; 9(6):488-497. PubMed ID: 37661840
[TBL] [Abstract][Full Text] [Related]
15. Plurihormonal pituitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification.
Ho DM; Hsu CY; Ting LT; Chiang H
Histopathology; 2001 Sep; 39(3):310-9. PubMed ID: 11532042
[TBL] [Abstract][Full Text] [Related]
16. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020.
Trouillas J; Jaffrain-Rea ML; Vasiljevic A; Raverot G; Roncaroli F; Villa C
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32098443
[TBL] [Abstract][Full Text] [Related]
17. Refractory Pit1 plurihormonal tumours and thyrotroph adenomas.
Nf L; Ai M
Pituitary; 2023 Apr; 26(2):182-186. PubMed ID: 37117845
[TBL] [Abstract][Full Text] [Related]
18. Observation of Clinicopathologic Features of Pituitary Adenoma With Neuronal Differentiation.
Zheng L; Yan X; Hu C; Zhang P; Chen Y; Zheng Q; Hu L; Wang M; Li G; Wu P; Jiang C; Tian J; Zhang S; Wang X
Front Endocrinol (Lausanne); 2022; 13():848762. PubMed ID: 35370935
[TBL] [Abstract][Full Text] [Related]
19. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
20. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.
Mete O; Gomez-Hernandez K; Kucharczyk W; Ridout R; Zadeh G; Gentili F; Ezzat S; Asa SL
Mod Pathol; 2016 Feb; 29(2):131-42. PubMed ID: 26743473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
